U.S. Serial No.: 10/593,852 Page 2 of 12

## Amendments to the Claims

Prior to substantive examination, Applicants have amended claims 1-8, 10-12, 14-23, 28, and 31 without any intention of disclaiming equivalents thereof; cancelled claims 9, 13, 24-27, 29-30, and 32-38 without prejudice to their subsequent reintroduction into this application or their introduction into a related application. The following list of claims replaces all prior versions and lists of claims in the application.

## What is claimed is:

- 1. (Currently amended) A method for identifying a compound capable of modulating influx of calcium ions into a eukaryotic cell comprising:
  - (a) providing a eukaryotic cell having a detectable reporter capable of translocation from the cytosol to associate with the plasma membrane in response to an influx of calcium ions,
  - (b) incubating the cell with a test compound,
  - (c) providing a stimulus for calcium influx, and,
  - (d) monitoring association of the detectable reporter with the plasma membrane and/or a decrease in the detectable reporter in the cytosol,

wherein the stimulus for calcium influx is provided before during and/or after before, during, and/or after incubation of the cell with the test compound.

- 2. (Currently Amended) [[A]] The method according to claim 1 comprising:
  - (a) monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from cytosol while
    - (i) providing a stimulus for calcium influx by incubating the cell in conditions that stimulate calcium influx, then
    - (ii) providing a test compound and incubating the cell with the test compound, and,

U.S. Serial No.: 10/593,852

Page 3 of 12

(b) comparing the association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol in the absence of the test compound with the association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol in the presence of the test compound,

wherein a difference in the association of the detectable reporter with the membrane and/or loss of detectable reporter from the cytosol in the presence of the test compound indicates that the test compound modulates calcium influx.

- 3. (Currently Amended) [[A]] <u>The</u> method <del>for</del> according to claim 2, for identifying a compound that antagonises calcium ion influx comprising:
  - (a) monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol while
    - (i) providing a stimulus for calcium influx by incubating the cell in conditions that stimulate calcium influx, then,
    - (ii) providing a test compound and incubating the cell with the test compound, and,
  - (b) comparing the association of the detectable reporter with the membrane and/or loss of detectable reporter from the cytosol in the absence and presence of the test compound,

wherein a decrease in association of the detectable reporter with the membrane and/or an increase in the detectable reporter in the cytosol following incubation of the cell with the test compound indicates that the test compound antagonises calcium ion influx.

- 4. (Currently Amended) [[A]] The method for according to claim 1 for identifying a compound that modulates calcium ion influx comprising:
  - (a) providing a control by monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the

U.S. Serial No.: 10/593,852

Page 4 of 12

cytosol while incubating the cell in conditions that stimulate calcium influx,

- (b) monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol while
  - (i) incubating the cell with a test compound, then
  - (ii) providing a stimulus for calcium influx by incubating the cell in conditions that stimulate calcium influx, and
- (c) comparing the association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol in the absence and presence of the test compound,

wherein a difference in association of the detectable reporter with the membrane and/or a difference in loss of the detectable reporter from the cytosol in the presence of the test compound compared to that in the absence of the test compound indicates that the test compound modulates calcium influx.

- 5. (Currently Amended) [[A]] <u>The</u> method according to claim 4 for identifying a compound that antagonises calcium ion influx comprising:
  - (a) providing a control by monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol while providing a stimulus for calcium influx by incubating the cell in conditions that stimulate calcium influx,
  - (b) monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol while
    - (i) incubating the cell with a test compound, then
    - (ii) providing a stimulus for calcium influx by incubating the cell in conditions that stimulate calcium influx, and
  - (c) comparing the association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol in the absence and presence of the test compound,

U.S. Serial No.: 10/593,852

Page 5 of 12

wherein a decrease in the association of the detectable reporter with the membrane and/or a decrease in loss of the detectable reporter from the cytosol in the presence of the test compound compared to that in the absence of the test compound indicates that the test compound antagonises calcium influx.

- 6. (Currently Amended) [[A]] <u>The</u> method according to claim 1, for identifying a compound that agonises calcium ion influx comprising:
  - (a) providing a eukaryotic cell having a detectable reporter capable of translocation from the cytosol to associate with the plasma membrane in response to an influx of calcium ions,
  - (b) providing a control by monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol while incubating the cell in conditions that stimulate calcium influx,
  - (c) monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol while
    - (i) providing a test compound and incubating the cell with the test compound, then,
    - (ii) providing a stimulus for calcium influx by incubating the cell in conditions that stimulate calcium influx, and,
  - (d) comparing the association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol in the absence and presence of the test compound,

wherein an increase in the association of the detectable reporter with the membrane and/or an increase in loss of detectable reporter from the cytosol in the presence of the test compound compared to that in the absence of the test compound indicates that the test compound agonises calcium influx.

U.S. Serial No.: 10/593,852

Page 6 of 12

7. (Previously Presented) A method for identifying a compound that agonises calcium ion influx comprising:

- (a) providing a eukaryotic cell having a detectable reporter capable of translocation from the cytosol to associate with the plasma membrane in response to an influx of calcium ions,
- (b) monitoring association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol before and after incubation of the cell with the test compound, and,
- (c) comparing the association of the detectable reporter with the membrane and/or loss of the detectable reporter from the cytosol in the absence and presence of the test compound,

wherein an increase in association of the detectable reporter with the membrane and/or a decrease in the detectable reporter in the cytosol following introduction of the test compound indicates that the test compound agonises calcium ion influx.

- 8. (Currently Amended) A method according to any preceding claim The method according to claim 1, wherein the cell is a mammalian cell.
- 9. (Cancelled)
- 10. (Currently Amended) A method according to any preceding claim The method according to claim 1, wherein the cell is capable of expressing, endogenously or ectopically, one or more calcium channel selected from the group comprising: TRP family channels, voltage-gated channels, ligand-gated channels and receptor-operated channels.
- 11. (Currently Amended) A method according to any preceding claim The method according to claim 10, wherein the detectable reporter is expressed within the eukaryotic cell.

U.S. Serial No.: 10/593,852

Page 7 of 12

12. (Currently Amended) [[A]] <u>The</u> method according claim 11, wherein a nucleic acid encoding the detectable reporter is stably integrated within the eukaryotic cell <u>or is transiently transfected into the eukaryotic cell.</u>

- 13. (Cancelled)
- 14. (Currently Amended) A method according to any one of claims 1 to 10 The method according to claim 1, wherein the detectable reporter is introduced into the cell.
- 15. (Currently Amended) A method according to any preceding claim The method according to claim 1, wherein the detectable reporter is or comprises CAPRI, or a derivative thereof which is capable of translocation to and association with the plasma membrane, and a detectable marker.
- 16. (Currently Amended) A method according to any preceding claim The method according to claim 15, wherein the detectable reporter is or comprises the CAPRI derivative R473S, and a detectable marker.
- 17. (Currently Amended) A method according to any preceding claim The method according to claim 15, wherein the detectable reporter is a CAPRI derivative comprising or consisting of the CAPRI C2A C2B domains, with wild type or mutated sequence, and a detectable marker.
- 18. (Currently Amended) A method according to any preceding claim The method according to claim 1, wherein the detectable reporter is a reporter labelled with a fluorescent marker.

U.S. Serial No.: 10/593,852 Page 8 of 12

19. (Currently Amended) A method The method according to claim 1 for identifying a compound that modulates calcium ion influx comprising:

- (a) providing a eukaryotic cell expressing FP-CAPRI or a FP-CAPRI derivative which is capable of translocation to and association with the plasma membrane;
- (b) (i) as a control, incubating the eukaryotic cell in the absence of test compound then providing a stimulus for calcium influx, and,
  - (ii) incubating the eukaryotic cell in the presence of a test compound, then providing a stimulus for calcium influx; or;
- (c) (i) as a control, incubating the eukaryotic cell and providing a stimulus for calcium influx in the absence of test compound, and,
  - (ii) incubating the eukaryotic cell and providing a stimulus for calcium influx, then providing a test compound; and,
- (d) monitoring fluorescence of the cell cytosol and/or plasma membrane during incubation in (b) or (c),

wherein a difference in fluorescence in the cytosol and/or at the plasma membrane in the presence of the test compound compared with that in the absence of the test compound is indicative that the test compound modulates calcium ion influx.

- 20. (Currently Amended) A method The method according to claim 7 for identifying a compound that agonises calcium ion influx comprising:
  - (a) providing a eukaryotic cell expressing FP-CAPRI or a FP-CAPRI derivative, which is capable of translocation to and association with the plasma membrane,
  - (b) incubating the eukaryotic cell in the presence of a test compound, and,
  - (c) monitoring fluorescence of the cell cytosol, and/or plasma membrane,

U.S. Serial No.: 10/593,852

Page 9 of 12

wherein a decrease in cytosolic fluorescence, and/or increase in plasma membrane fluorescence following addition of the test compound is indicative that the test compound agonises calcium ion influx.

- 21. (Currently Amended) A method The method according to claim 1 for identifying a compound that antagonises calcium ion influx comprising:
  - (a) providing a eukaryotic cell expressing FP-CAPRI or a FP-CAPRI derivative which is capable of translocation to and association with the plasma membrane,
  - (b) incubating the eukaryotic cell and providing a stimulus for calcium ion influx,
  - (c) monitoring fluorescence of the cell cytosol and/or plasma membrane,
  - (d) introducing a test compound to the incubation mixture,
- (e) monitoring fluorescence of the cell cytosol and/or plasma membrane, wherein an increase in cytosolic fluorescence and/or a decrease in plasma membrane fluorescence following addition of the test compound is indicative that the test compound antagonises calcium ion influx.
- 22. (Currently Amended) A method The method according to claim 7 for identifying a compound that agonises calcium ion influx comprising:
  - (a) providing a eukaryotic cell expressing FP-CAPRI or a FP-CAPRI derivative which is capable of translocation to and association with the plasma membrane,
  - (b) incubating the eukaryotic cell in the presence of a test compound and,
- (c) monitoring fluorescence of the cell cytosol and/or plasma membrane, wherein a decrease in cytosolic fluorescence and/or an increase in plasma membrane fluorescence following addition of the test compound is indicative that the test compound agonises calcium ion influx.

U.S. Serial No.: 10/593,852

U.S. Serial No.: 10/ Page 10 of 12

23. (Currently Amended) A method according to any one of claims 18 to 22 The method according to claim 19, wherein the fluorescent marker is selected from the group consisting of a quantum dot and a fluorescent protein.

24-27. (Cancelled)

28. (Currently Amended) A method according to any one of claims 18 to 27 The method according to claim 19, wherein monitoring is performed by fluorescence microscopy.

29-30. (Cancelled)

31. (Currently Amended) A method according to claim 30 The method according to claim 28, wherein monitoring association of the detectable reporter with the plasma membrane and/or decrease of detectable reporter in the cytosol is assessed by calculating the relative translocation parameter (1-Ft/Fo) at one or more time points, wherein Fo is the fluorescence in a region(s) of interest at the start of monitoring and Ft is fluorescence in a region(s) of interest at a later time point or points.

32-38. (Cancelled)